DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced the completion of the enrollment of 20 patients in its pilot clinical trial of the Impella® 2.5 Circulatory Support System. The trial will be completed after the Company has concluded all necessary post-enrollment patient monitoring.
